PetVivo (NASDAQ:PETV) vs. PAVmed (NASDAQ:PAVM) Head-To-Head Survey

PAVmed (NASDAQ:PAVM) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares PAVmed and PetVivo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	-1,508.12%	N/A	-102.44%
PetVivo	-1,036.82%	-1,038.50%	-266.37%

Earnings and Valuation

This table compares PAVmed and PetVivo”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$2.45 million	5.06	-$64.18 million	($9.10)	-0.13
PetVivo	$1.05 million	11.24	-$10.95 million	($0.79)	-0.75

PetVivo has lower revenue, but higher earnings than PAVmed. PetVivo is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

PAVmed has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for PAVmed and PetVivo, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	0	0	1	1	3.50
PetVivo	0	0	0	0	N/A

PAVmed presently has a consensus price target of $21.00, suggesting a potential upside of 1,664.71%. Given PAVmed’s higher probable upside, analysts plainly believe PAVmed is more favorable than PetVivo.

Institutional and Insider Ownership

19.9% of PAVmed shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 12.6% of PAVmed shares are held by insiders. Comparatively, 20.1% of PetVivo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

About PetVivo

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.